Our Mission

PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.

Click the orange button to the right to learn more.

Alpha-1 Antitrypsin for Graft-Versus-Host Disease After Allogeneic Stem Cell Transplant

Share Button

Alpha-1 Antitrypsin for Graft-Versus-Host Disease After Allogeneic Stem Cell Transplant. Can alpha-1 antitrypsin (AAT) help treat graft-versus-host disease after an allogeneic stem cell transplant?

Years ago, I first wrote about alpha-1 antitrypsin because laboratory research suggested that this naturally occurring protein might reduce graft-versus-host disease (GVHD). At the time, the evidence was largely preclinical.

That has changed.

Researchers have now studied intravenous alpha-1 antitrypsin in people with acute GVHD, including patients whose GVHD did not respond adequately to corticosteroids and patients who had already received other treatments.

The results are encouraging enough to warrant attention—but AAT remains an investigational/off-label approach to GVHD rather than an established standard treatment.

For patients and survivors considering an allogeneic hematopoietic stem cell transplant (allo-HCT), that distinction matters.

I am a Multiple Myeloma survivor. My experience as a long-term survivor of this incurable blood cancer has taught me that there is a world of evidence-based, but not standard-of-care therapies that can ease or eliminate the collateral damage caused by conventional toxic therapies.

I work with MM patients to research and identify those therapies that can enhance their treatments while reducing or eliminating their short-, long-term, and late-stage side effects of therapy.

Are you considering a bone marrow transplant? Have you had a BMT and are experiencing GvHD?  Scroll down the page, post a question or comment, and I will reply ASAP.

Thank you,

David Emerson

  • Cancer Survivor
  • Cancer Coach
  • Director PeopleBeatingCancer

Concepts Central to Managing Your Cancer-


Possible Therapies-


What Is Graft-Versus-Host Disease?

GVHD can occur after an allogeneic stem cell transplant, in which stem cells come from a donor. The donor immune cells recognize some of the recipient’s tissues as foreign and attack them.

Acute GVHD commonly affects the:

  • Skin
  • Gastrointestinal tract
  • Liver

Chronic GVHD can affect many more organs and may behave somewhat like a complex autoimmune disorder. GVHD does not occur after an autologous stem cell transplant in the same way because an autologous transplant uses the patient’s own stem cells.

This distinction is particularly important for people with multiple myeloma because the overwhelming majority of stem cell transplants performed for myeloma are autologous rather than allogeneic.

For more background, see:


What Is Alpha-1 Antitrypsin?

Alpha-1 antitrypsin (AAT), also called alpha-1 proteinase inhibitor, is a naturally occurring protein produced primarily by the liver. Its best-known function is protecting tissues from enzymes released during inflammation.

People with inherited alpha-1 antitrypsin deficiency can develop lung and liver disease. Plasma-derived AAT replacement products are FDA-approved for certain patients with severe AAT deficiency.

Researchers became interested in AAT for GVHD for a different reason: its anti-inflammatory and immunomodulatory properties.

Preclinical studies suggested AAT could reduce inflammatory signaling and alter the balance between regulatory T cells and inflammatory effector T cells. That raised an intriguing question:

Could AAT calm the damaging immune response responsible for GVHD without simply adding another powerful immunosuppressive drug?

Researchers have now begun answering that question in humans.


AAT for Steroid-Refractory Acute GVHD

One of the important early human studies was a prospective multicenter phase II trial involving 40 patients with steroid-refractory acute GVHD.

Patients received intravenous AAT twice weekly for four weeks. Researchers reported:

  • 65% overall response rate at day 28
  • 35% complete response rate
  • Responses across GVHD target organs
  • 73% of responding patients maintained their responses at day 60 without additional immunosuppressive therapy
  • No drug-related adverse events reported in the study

The investigators concluded that AAT was well tolerated and potentially effective in steroid-refractory acute GVHD.

Research:
Alpha-1-Antitrypsin Infusion for Treatment of Steroid-Resistant Acute GVHD — Blood

These results were encouraging, but this was a single-arm phase II study—not a randomized trial demonstrating that AAT was superior to established therapy.

That distinction is important.


More Recent Evidence

A 2025 multicenter retrospective study evaluated 17 patients treated with AAT for steroid-refractory acute GVHD. The reported overall response rate was 70.6%. The researchers reported no grade 3-4 anemia, thrombocytopenia or neutropenia following AAT treatment, although infections occurred in several patients.

Again, the results are encouraging—but 17 patients is a small population and retrospective studies cannot establish effectiveness as reliably as randomized controlled trials.

Research:
What Is the Role of Alpha-1 Antitrypsin in the Management of Acute GVHD? — PubMed


AAT After Other GVHD Treatments Have Failed

Perhaps the most interesting recent evidence comes from patients with particularly difficult-to-treat acute GVHD. A 2026 real-world study evaluated 33 patients with steroid-refractory acute GVHD treated with AAT. Many had already received multiple therapies, including ruxolitinib.

AAT was administered at 120 mg/kg intravenously twice weekly for four weeks, followed by weekly maintenance treatment for another four weeks. Researchers reported:

  • 66.7% overall response at day 28
  • 57.6% overall response at day 56
  • 51.5% durable response
  • Responses even among patients with severe grade III-IV disease
  • Reduced corticosteroid requirements

No patients stopped AAT because of treatment-related side effects. However, infections were common. By day 100, bacterial infections had occurred in 63.6% of patients and viral infections in 72.7%.

These were very ill and heavily pretreated transplant patients, so the study cannot establish that AAT itself caused those infections. Most importantly, this was a real-world observational analysis—not a randomized trial directly establishing AAT as superior to another therapy.

Research:
Real-World Experience of Alpha-1 Antitrypsin in Treatment-Refractory Acute GVHD — Transplantation and Cellular Therapy


AAT Has Not Worked in Every GVHD Setting

This is an important part of the evidence. Researchers have also investigated whether giving AAT before clinical GVHD develops could prevent steroid-refractory disease in high-risk transplant patients. In one biomarker-guided study, 30 high-risk patients received AAT and were compared with 90 high-risk controls.

AAT was well tolerated—but it did not significantly reduce steroid-refractory GVHD. Steroid-refractory GVHD developed in:

  • 20% of AAT-treated patients
  • 14% of controls

The difference was not statistically significant. AAT also failed to significantly reduce grade II-IV or grade III-IV acute GVHD.

Research:
Biomarker-Guided Preemption of Steroid-Refractory GVHD With Alpha-1 Antitrypsin — Blood Advances

This negative study is important because it tells us something about where AAT may—or may not—eventually fit.

A therapy that shows activity in treating established inflammatory GVHD does not necessarily prevent GVHD from developing.


What Is the Standard Treatment for Acute GVHD?

This is where the original version of this article needs the most updating. According to 2026 clinical guidance from the American Society for Transplantation and Cellular Therapy (ASTCT):

Systemic corticosteroids remain the recommended first-line systemic treatment for acute GVHD. For patients whose acute GVHD does not adequately respond to corticosteroids, ruxolitinib is the established second-line standard.

There is currently no consensus standard third-line therapy.

Research:
ASTCT Clinical Management of Acute Graft-Versus-Host Disease — PubMed

The FDA originally approved ruxolitinib for steroid-refractory acute GVHD in patients aged 12 and older in 2019 and subsequently approved it for certain patients with chronic GVHD.

FDA:
Ruxolitinib GVHD Approvals

Therefore, based on the evidence available today, I would not consider AAT a substitute for established first- or second-line GVHD therapy.

The more interesting question may be whether AAT eventually develops a role in treatment-refractory GVHD after corticosteroids and/or ruxolitinib have failed or cannot be tolerated.

That question remains open.


PBC Evidence Rating: Alpha-1 Antitrypsin for Acute GVHD

Therapy/use Evidence PBC rating What the evidence suggests
Corticosteroids for acute GVHD Guidelines + extensive clinical experience Strong Established first-line systemic treatment
Ruxolitinib for steroid-refractory acute GVHD Randomized clinical trials + FDA approval Strong Established second-line therapy
AAT for steroid-refractory acute GVHD Phase II + retrospective/real-world studies Moderate / emerging Encouraging response rates, but randomized confirmatory evidence is still needed
AAT after multiple prior GVHD therapies Small real-world studies Preliminary / emerging Potential option worth further investigation
AAT to prevent/preempt acute GVHD Clinical studies including negative results Insufficient Current evidence does not establish preventive benefit

How I interpret this evidence

I think AAT is considerably more interesting today than when I first wrote about it. The original research was essentially saying:

“This works in experimental GVHD. Perhaps we should test it in humans.”

Researchers did. And some patients with extremely difficult-to-treat acute GVHD have responded. But that is very different from saying that AAT has been proven to treat GVHD better than current standard therapies.

It hasn’t.

The evidence currently supports continued clinical investigation and discussion with a transplant specialist, particularly when acute GVHD is refractory to established treatments.


What About Multiple Myeloma?

This subject has special relevance to PeopleBeatingCancer because I underwent an autologous stem cell transplant for multiple myeloma in December 1995. My transplant was autologous, meaning my own stem cells were returned to me.

An allogeneic transplant uses donor stem cells. That donor immune system can sometimes produce a graft-versus-myeloma effect—but it also creates the possibility of GVHD and substantial treatment-related mortality.

Because modern myeloma therapy now includes proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, CAR-T therapy, bispecific antibodies and other highly active treatments, allogeneic transplantation occupies a much smaller and more specialized role in myeloma than autologous transplantation.

For selected patients with particularly difficult or high-risk disease, however, allo-HCT may still be discussed at specialized transplant centers.

PeopleBeatingCancer:
Allogeneic SCT for Myeloma: “Curative Potential” for High-Risk MM?

And because GVHD is one of the defining risks of an allogeneic transplant, patients considering one should understand both the potential graft-versus-cancer benefit and the possibility of acute and chronic GVHD.


Questions to Ask Your Transplant Specialist

If you develop acute GVHD following an allogeneic transplant, useful questions include:

  1. What grade of acute GVHD do I have?
  2. Which organs are involved?
  3. Am I considered standard-risk or high-risk?
  4. What is my initial corticosteroid treatment?
  5. How will you determine whether my GVHD is steroid-refractory?
  6. If steroids don’t work, when would you consider ruxolitinib?
  7. What infection-prevention measures will I need during additional immunosuppression?
  8. If my GVHD becomes refractory to multiple therapies, are clinical trials available?
  9. Is alpha-1 antitrypsin being used or studied at this transplant center?
  10. Would AAT ever be reasonable in my particular situation?

The Bottom Line

Alpha-1 antitrypsin is no longer merely an interesting laboratory treatment for GVHD. Human studies have reported meaningful responses in some patients with steroid-refractory and treatment-refractory acute GVHD.

That makes AAT an intriguing investigational therapy. But the evidence is not yet strong enough to place AAT alongside corticosteroids or ruxolitinib as established standard treatment.

For me, the most interesting potential role for AAT is further down the treatment pathway—particularly for people with severe acute GVHD who have already failed established therapies.

That is exactly the type of difficult clinical situation where carefully studied new approaches are needed.

Additional PeopleBeatingCancer Reading

Medical note: GVHD can become serious quickly. New rash, persistent diarrhea, nausea/vomiting, jaundice, abnormal liver tests or other symptoms following an allogeneic transplant should be reported promptly to the transplant team. Supplements or complementary therapies should not be started during active GVHD without discussing them with the transplant team because of potential interactions, organ toxicity and infection risks.


Stem cell transplantation:


Hematopoietic stem cell transplantation

“Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood.[1][2] It may be autologous (the patient’s own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from an identical twin)…”

Natural Enzyme Provides Potential New Approach for Treating Graft-Vs.-Host Disease

“A natural enzyme derived from human blood plasma showed potential in significantly reducing the effects of graft-vs.-host disease, a common and deadly side effect of lifesaving bone marrow transplants…

In this study, which appears in the Proceedings of the National Academy of Sciences, researchers used alpha-1-antitrypsin in mice that received allogeneic bone marrow transplants. The drug significantly reduced mortality from graft-vs.-host disease, compared to control mice who did not receive the drug.

In addition, alpha-1-antitrypsin reduced the number of inflammatory cells called T Effector cells that are known to be present in graft-vs.-host disease. It also increased the number of T-regulatory cells, which immunologists believe play a positive role in immune responses.”

Alpha-1 Antitrypsin for Graft-Versus-Host Disease Alpha-1 Antitrypsin for Graft-Versus-Host Disease

Leave a Comment:

6 comments
Sibling Cord Blood May Offer Best Chance For Bone Marrow Transplant - PeopleBeatingCancer says 7 years ago

[…] Enzyme alpha-1-antitrypsin May Reduce Graft-Vs.-Host Disease (GvHD) […]

Reply
Stem Cell Transplant for Blood Cancers- What you Need to Know - PeopleBeatingCancer says 8 years ago

[…] Enzyme alpha-1-antitrypsin May Reduce Graft-Vs.-Host Disease (GvHD) […]

Reply
Jean Dugan says 8 years ago

My daughter had bmt 6/6/18. Out in 12 days. Excellent CBC. Early July lv enzymes went up. I complained. No one listened. Now they think GVHD of liver.

Oops. I already wrote you. Sorry.

Can you help me with this? Thanks

Reply
    David Emerson says 8 years ago

    Hi Jean,

    No problem writing me twice. I don’t remember what I said last time but I think that 1) the article you read cites alpha-1-antitrypsin as possibly helping your daughter. You should ask your oncologist. Secondly, there are a number of evidence-based non-toxic therapies that have been shown to reduce or health stem cell transplant side effects. For example, an antioxidant called milk thistle has been shown to help heal the liver- it is possible that your daughter is having problems with her liver due to past chemo and this is why her enzymes increases.

    David Emerson

    Reply
Jean says 8 years ago

My daughter had a BMT 6/6. Elevated liver enzymes now. Doc thinks graft vs host. Wants to give prednesone….argh.

Reply
    David Emerson says 8 years ago

    Hi Jean,

    Your oncologist is prescribing the standard-of-care therapy, prednisone, for your daughter’s elevated liver enzymes. High dose steroids have been shown to boost one’s immune system.

    David Emerson

    Reply
Add Your Reply